New gout pill aims to tame uric acid in Mid-Stage trial
NCT ID NCT07498647
First seen Mar 28, 2026 · Last updated May 19, 2026 · Updated 8 times
Summary
This study tests a new tablet called BR2251 to see if it safely lowers uric acid levels in people with gout and high uric acid. About 160 adults aged 18 to 75 will receive either a low, medium, or high dose of BR2251 or a control drug for 12 weeks. The goal is to find the best dose for controlling uric acid and reducing gout attacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT AND HYPERURICEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.